BioChem Pharma's first-half results:
This article was originally published in Clinica
Executive Summary
BioChem Pharma, the Canadian target of much takeover speculation in recent weeks, has reported sales of Can$93.8 million ($69 million) in the first half, up from Can$39.5 million last year, supported by its acquisition in 1994 of Serono Diagnostics. BioChem's net loss fell to Can$3.3 million compared with Can$4.6 million. BioChem has denied rumours of a takeover approach from UK-based Glaxo Wellcome (see Clinica No 668, p 17).
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.